Krop Julie 4

4 · Aquestive Therapeutics, Inc. · Filed Jun 24, 2026

AI-generated summary of this filing

Updated Jun 24, 2026

Aquestive (AQST) Director Julie Krop Exercises Options, Sells 25,000 Shares

What Happened

Julie Krop, a director of Aquestive Therapeutics (AQST), exercised 25,000 stock options at $0.71 per share (cost $17,830) and the same day sold 25,000 shares in the open market at $5.02 per share for $125,393. The transactions were reported on a Form 4 covering activity dated 2026-06-23. This is a net sale of shares (often routine) executed under a pre-established plan.

Key Details

Transaction date: June 23, 2026
Exercise: 25,000 shares exercised at $0.71 each — total cost reported $17,830 (code M)
Sale: 25,000 shares sold at $5.02 each — total proceeds $125,393 (code S)
Additional line: a derivative (M) disposition of 25,000 shares at $0.00 is reported on the form (see footnotes)
Footnotes: F1/F2 — transactions were effected pursuant to a Rule 10b5-1 trading plan; F3 — the option was granted June 22, 2022 and is fully vested
Filing timeliness: Report filed 2026-06-24 for activity on 2026-06-23 (timely)
Shares owned after transaction: Not specified in the provided filing excerpt

Context

The Form 4 shows an exercise and a same-day sale, consistent with a planned sell under a 10b5-1 arrangement; the filing itself indicates the sales were made pursuant to a 10b5-1 trading plan. Derivative-code M lines indicate option exercise/conversion. The filing is factual and does not state the insider's motivation.

Form 4

Period: 2026-06-23

Director

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-06-23$0.71/sh+25,000$17,830→ 25,000 total
Sale
Common Stock
[F2]
2026-06-23$5.02/sh−25,000$125,393→ 0 total
Exercise/Conversion
Non-Qualified Stock Option (right to buy)
[F1][F3]
2026-06-23−25,000→ 0 total
Exercise: $0.71Exp: 2032-06-22→ Common Stock (25,000 underlying)

Footnotes (3)

[F1]This is a scheduled exercise from 10b5-1 trading plan. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.
[F2]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.
[F3]This option was granted on June 22, 2022 and is fully vested.

Signature

/s/ Thomas Zalewski, as Attorney-In-Fact|2026-06-24

1 file